LCZ696

LCZ696: Approved as Entresto

History: During its development by Novartis, Entresto was known as LCZ696. 

It was approved under the FDA's priority review process on July 7, 2015. It was also approved in Europe in 2015.

LCZ696 aka Entresto

Angiotensin Receptor Neprilysin Inhibitor

Mechanism Of Action

Angiotensin Receptor Blocker + Neprilysin Inhibition 

LCZ 696:  Inhibition Of  Neprilysin ( Neprilysin: Natriuretic Peptide Breakdown)

Results

Paramount Trial

Snapshot

Research To Medicine

Entresto: Blockbuster Drug of 2015